Page 6 - Andreas Muehler News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Immunic (IMUX) Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

Immunic (IMUX) Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAndreas muehlerDaniel vittImmunic incDevelopment programsChief executive officerChief medical officer

Immunic Inc reports positive data from maintenance phase of Phase 2 CALDOSE-1 trial

Immunic Inc reports positive data from maintenance phase of Phase 2 CALDOSE-1 trial
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

United statesAndreas muehlerDaniel vittImmunic incEastern europe

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

– 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of.

United statesAndreas muehlerJessica breuDaniel vittDeprioritize izumerogantEdna kaplanPaula schwartzExchange commissionRx communications groupDevelopment programsPrnewswire immunic incImmunic incClinical remissionVidofludimus calciumOnce daily doseEndoscopic healing

EQS-News: Immunic, Inc : Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

Issuer: Immunic, Inc. / Key word(s): Study results/Strategic Company Decision Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe

United statesPaula schwartzAndreas muehlerDeprioritize izumerogantJessica breuEdna kaplanDaniel vittExchange commissionDistribution servicesStrategic company decisionDevelopment programsImmunic incRx communications groupReports positive dataMaintenance phaseVidofludimus calcium

EQS-News: Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis

Issuer: Immunic, Inc. / Key word(s): Study results/Strategic Company Decision Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis 05.04.2023 / 12:30 CET/CEST The issuer is solely responsible for the cont.

United statesDaniel vittEdna kaplanJessica breuAndreas muehlerPaula schwartzDeprioritize izumerogantRx communications groupExchange commissionStrategic company decisionDistribution servicesImmunic incDevelopment programsReports positive dataMaintenance phaseVidofludimus calcium